Vanguard Capital Management
ANIX icon

Vanguard Capital Management’s Anixa Biosciences ANIX Stock Holding History

Vanguard Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72M Buy
1,329,852
+14,870
+1% +$41.4K ﹤0.01% 3220
2026
Q1 		$3.39M Buy
+1,314,982
New +$3.89M ﹤0.01% 3197

Other funds holding ANIX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Vanguard Capital Management's ANIX Position: Q2 2026 in Review

Vanguard Capital Management increased its Anixa Biosciences (ANIX) stake by 1.1% in Q2 2026, buying an estimated $41.4K and bringing the position to 1,329,852 shares worth $3.72M. The position accounts for ﹤0.01% of the portfolio, ranked #3220.

Vanguard Capital Management first reported a position in ANIX in Q1 2026 and has held it in 2 quarters since. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

  • Vanguard Capital Management held 1,329,852 shares of Anixa Biosciences worth $3.72M as of Q2 2026.
  • Vanguard Capital Management bought 14,870 Anixa Biosciences shares in Q2 2026, an estimated $41.4K.
  • Anixa Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3220 holding.
  • Vanguard Capital Management first reported a position in Anixa Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.